GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keymed Biosciences Inc (HKSE:02162) » Definitions » EPS without NRI

Keymed Biosciences (HKSE:02162) EPS without NRI : HK$-3.09 (TTM As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Keymed Biosciences EPS without NRI?

Keymed Biosciences's earnings per share without non-recurring items for the six months ended in Jun. 2024 was HK$-1.40. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-3.09.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 25.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Keymed Biosciences's EPS without NRI or its related term are showing as below:

HKSE:02162' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -24.1   Med: 0.55   Max: 25.2
Current: 25.2

During the past 5 years, Keymed Biosciences's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 25.20% per year. The lowest was -24.10% per year. And the median was 0.55% per year.

HKSE:02162's 3-Year EPS without NRI Growth Rate is ranked better than
74.9% of 1239 companies
in the Biotechnology industry
Industry Median: 4.6 vs HKSE:02162: 25.20

Keymed Biosciences's EPS (Diluted) for the six months ended in Jun. 2024 was HK$-1.39. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-3.08.

Keymed Biosciences's EPS (Basic) for the six months ended in Jun. 2024 was HK$-1.39. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-3.08.


Keymed Biosciences EPS without NRI Historical Data

The historical data trend for Keymed Biosciences's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keymed Biosciences EPS without NRI Chart

Keymed Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
-0.69 -3.58 -29.60 -1.32 -1.50

Keymed Biosciences Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 -1.34 0.18 -1.70 -1.40

Competitive Comparison of Keymed Biosciences's EPS without NRI

For the Biotechnology subindustry, Keymed Biosciences's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Keymed Biosciences's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Keymed Biosciences's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Keymed Biosciences's PE Ratio without NRI falls into.



Keymed Biosciences EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-3.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Keymed Biosciences  (HKSE:02162) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Keymed Biosciences EPS without NRI Related Terms

Thank you for viewing the detailed overview of Keymed Biosciences's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Keymed Biosciences Business Description

Traded in Other Exchanges
N/A
Address
No. 18 BioTown Middle Road, Building D2, Tianfu International BioTown, Chengdu, Sichuan, CHN, 610219
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
Executives
Chen Bo 2201 Interest of corporation controlled by you
Eagle Hero Management Limited 2101 Beneficial owner
Trident Trust Company (hk) Limited 2301 Trustee
Moonshot Holdings Limited 2101 Beneficial owner
Hh Kny Holdings Limited
Hillhouse Investment Management, Ltd.
Boyu Capital Group Holdings Ltd
Xyxy Holdings Ltd.
Tong Xiaomeng

Keymed Biosciences Headlines

No Headlines